Mangalam Drugs and Organics share news and announcements
NSE: MANGALAMBSE: 532637Pharmaceuticals & BiotechnologySmall Cap
Last close ₹28.65down ₹0.92 (3.11%)BSE ₹28.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹29.57.
52-week range of traded prices to 23 Oct 2026
₹22.80Low, 29 Dec 2025₹71.99High, 23 Oct 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹45 Cr3,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 0.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −30.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −12.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 1.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 19,55176.4% delivered
Mangalam Drugs and Organics share news and announcements
527 announcements, routine notices left out, newest first. Page 7 of 11.
Jul 2019
22 Jul · Legal
The exchange asked on 22 Jul 2019
19 Jul · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 08-Jul-2019, about the following changes: 1. Resignation of Ms. Nikita Bavishi as Company Secretary & Compliance officer of the company w.e.f. closure of business hours of 08th July, 2019. 2. Appointment of Ms. Geeta G. Karira as Company Secretary & Compliance officer of the company w.e.f. 09th July, 2019. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.8 Jul · Change in Company Secretary/Compliance Officer
8 Jul · Management
8 Jul · Board meeting
Jun 2019
May 2019
9 May · Board meeting
Apr 2019
16 Apr · Management
Mar 2019
Feb 2019
14 Feb · Legal
Significant movement in price has been observed in Mangalam Drugs And Organics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.11 Feb · Board meeting
Jan 2019
Dec 2018
Nov 2018
14 Nov · Board meeting
Sep 2018
Aug 2018
14 Aug · Management
14 Aug · Board meeting
May 2018
28 May · Management
28 May · Board meeting
Feb 2018
12 Feb · Board meeting